[
  {
    "ts": null,
    "headline": "Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism",
    "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 to $81 on September 24. The firm attributed the change in part to growing interest in Incyte’s ‘989 CALR antibody program ahead of expected ASH (American […]",
    "url": "https://finnhub.io/api/news?id=991b538dcddf17cfd7739690c32b888cab7677620ae07a412333d82c6e737da5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759383338,
      "headline": "Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism",
      "id": 136955723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 to $81 on September 24. The firm attributed the change in part to growing interest in Incyte’s ‘989 CALR antibody program ahead of expected ASH (American […]",
      "url": "https://finnhub.io/api/news?id=991b538dcddf17cfd7739690c32b888cab7677620ae07a412333d82c6e737da5"
    }
  },
  {
    "ts": null,
    "headline": "2 Reasons to Like INCY and 1 to Stay Skeptical",
    "summary": "Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=de73f551f2dd76ae74eb2927645c40fd0f3e06127eeb246c75da02fc0861ef14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759377815,
      "headline": "2 Reasons to Like INCY and 1 to Stay Skeptical",
      "id": 136955724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=de73f551f2dd76ae74eb2927645c40fd0f3e06127eeb246c75da02fc0861ef14"
    }
  }
]